piretanide

06/15/1989 - "In patients with acute decompensated heart failure (group 2) piretanide led to a significant reduction in mean pulmonary artery pressure (from 42 +/- 13 to 37 +/- 12 mm Hg; p less than 0.05) within 15 minutes after administration, i.e. "
08/01/1989 - "When compared with another group of healthy volunteers, patients with congestive heart failure had reduced total body clearance of piretanide of about 50% which was attributable to a diminished renal but not non-renal clearance. "
08/01/1989 - "Efficacy and pharmacokinetics of piretanide in patients with congestive heart failure."
06/15/1989 - "Thus, the administration of piretanide had a positive effect on hemodynamics in patients with chronic as well as in patients with acute decompensated heart failure. "
06/15/1989 - "Eight patients with chronic heart failure classified as NYHA class II to III (group 1) and nine patients with acute decompensated heart failure classified as NYHA class IV (group 2) were treated with piretanide at a dosage of 12 mg administered intravenously. "

01/01/1989 - "2. Piretanide (30 mg/kg) prevented development of hypertension and produced a significant reduction in blood pressure from the 2nd week of the treatment. "
01/01/1983 - "A double-blind trial was carried out in three parallel groups of patients with mild to moderate hypertension to assess the efficacy and tolerance of piretanide given as a single dose of 3 mg, 6 mg or 12 mg per day over a period of 12 weeks. "
06/03/1985 - "Piretanide for hypertension."
01/01/1985 - "A single-blind study was carried out in 22 out-patients with mild to moderate hypertension to investigate the effects of piretanide capsules on systolic and diastolic blood pressure during standardized ergometric and isometric exercise. "
01/01/1985 - "In a randomised double blind study in patients with mild to moderate hypertension, piretanide 6 mg once and twice daily significantly reduced both supine and erect blood pressure. "

01/01/1983 - "Piretanide appeared to be effective in advanced renal insufficiency. "
01/01/1988 - "Multiple daily doses of piretanide of maximally 24 mg are recommended for optimal efficiency in renal failure. "
01/01/1985 - "The present data suggest that single daily doses of piretanide will not result in accumulation, even when high doses are administered to patients with advanced renal failure."
01/01/1985 - "Piretanide 60 mg was administered intravenously over 30 min to 15 men with different degrees of renal failure. "
01/01/1984 - "Pharmacokinetics of high doses of piretanide in moderate to severe renal failure."

07/01/1993 - "To verify whether this protective effect is also shared by other loop diuretics, we investigated the effect of inhaled piretanide on the bronchial obstructive response to ultrasonically nebulized distilled water (UNW) in ten patients with moderate, stable asthma. "
07/01/1993 - "These data indicate that inhaled piretanide is as effective as furosemide in preventing UNW-induced asthma, and this effect is unrelated to their diuretic potency."
11/01/1992 - "Protective effect of loop diuretics, piretanide and frusemide, against sodium metabisulphite-induced bronchoconstriction in asthma."

01/01/1986 - "In a randomized, double-blind parallel group study the 24-hour hypotensive effect of piretanide and its influence on biochemical variables were compared with those of placebo in patients with mild to moderate essential hypertension. "
01/01/1986 - "Piretanide in the treatment of essential hypertension. "
01/01/1985 - "The effects of piretanide capsules on blood pressure during ergometric and isometric work loads in patients with mild to moderate essential hypertension."
09/15/1993 - "To test the dose responses of piretanide, ramipril, and their combination in patients with essential hypertension, a prospective, randomized, double-blind, placebo-controlled trial was conducted in 480 patients. "
01/01/1985 - "The efficacy and tolerability of penbutolol alone and in combination with piretanide at two dose levels were investigated in a double-blind parallel group study in patients with mild to moderate essential hypertension. "